Compass Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates on profitability, with a GAAP EPS loss of $0.13 compared to the $0.11 expected. R&D and G&A expenses rose significantly YoY, leading to an operating loss of $27.0M, which was roughly 28% wider than the consensus mean of $21.0M. Despite the bottom-line miss, the clinical pipeline remains robust with a BLA filing for tovecimig anticipated later this year and a cash runway extended into 2028.